Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...
Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...
The National Medical Products Administration in China has approved two Sanofi (SNY) medicines for rare hematologic diseases: Qfitlia for ...
Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...
Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism ...
Sanofi’s Qfitlia (fitusiran) has been approved by the US Food and Drug Administration (FDA) as the first therapy to treat haemophilia A or B regardless of inhibitor status. The drug has been ...
Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback